Major global healthcare Johnson & Johnson has announced the expansion of its TB program in India. It was announced with 50th Union World Conference on Lung Health to be held in Hyderabad.
Through a series of new partnerships with several multilateral and non-governmental organizations as well as the Government of India, J&J company aims to support the country’s effort to end TB by 2025, as outlined in National Strategic Plan for TB Elimination. A major part of the J&J 10-year comprehensive initiative to achieve a TB free world, this expanded India program aims to provide access to MDR-TB, improve detection of undiagnosed cases, build critical health system capacity and raise awareness among masses. J&J has pledged to invest $500 million over the next four years to help in eliminating TB and HIV endemics.
Sarthak Ranade managing Director, J&J added “TB is a dangerous disease which claims more than half a million lives in India annually. We have better tools than before which illuminates a ray of hope for patients, families, and communities suffering from TB. The need of the hour is coordinated action. We are gratified to collaborate with our partners to address the challenges presented by TB and DR-TB.”
J&J expanded the TB program in India includes improving diagnosis rates and linkage to care. As part of this new effort with ‘The Foundation for Innovative New Diagnostics (FIND)’, In collaboration with India’s Revised National Tuberculosis Control Program (RNTCP), is expected to provide technical assistance to build capacity and establish new TB culture and drug-susceptibility testing facilities in at least seven sites across India-with a focus on high-burden TB states like Maharastra, HP, and Tamil Nadu.